WO2024067463A1 - Dérivé de benzo[7]annulène, composition pharmaceutique le comprenant, et utilisations médicales associées - Google Patents

Dérivé de benzo[7]annulène, composition pharmaceutique le comprenant, et utilisations médicales associées Download PDF

Info

Publication number
WO2024067463A1
WO2024067463A1 PCT/CN2023/121015 CN2023121015W WO2024067463A1 WO 2024067463 A1 WO2024067463 A1 WO 2024067463A1 CN 2023121015 W CN2023121015 W CN 2023121015W WO 2024067463 A1 WO2024067463 A1 WO 2024067463A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
compound
alkyl
mmol
substituted
Prior art date
Application number
PCT/CN2023/121015
Other languages
English (en)
Chinese (zh)
Inventor
吴杰
叶阳亮
王昊
刘治国
Original Assignee
苏州阿尔脉生物科技有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 苏州阿尔脉生物科技有限公司 filed Critical 苏州阿尔脉生物科技有限公司
Publication of WO2024067463A1 publication Critical patent/WO2024067463A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/14—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/46—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
    • C07C381/10—Compounds containing sulfur atoms doubly-bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D233/16—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
    • C07D313/02—Seven-membered rings
    • C07D313/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D313/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D333/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines
    • C07F9/53—Organo-phosphine oxides; Organo-phosphine thioxides

Definitions

  • the present invention belongs to the field of medicine, and specifically relates to a benzo[7]cycloolefin derivative, and specifically relates to a benzo[7]cycloolefin derivative as a hypoxia inducible factor-2 ⁇ (HIF-2 ⁇ ) inhibitor, and its use.
  • HIF-2 ⁇ hypoxia inducible factor-2 ⁇
  • Kidney cancer also known as renal cell carcinoma, is one of the 10 most common cancers worldwide and one of the most lethal tumors of the urinary system. Histopathology divides kidney cancer into three main subtypes: clear cell renal cell carcinoma (ccRCC, 70-75%), papillary renal cell carcinoma (pRCC, 10-16%), and pheochromocytic renal cell carcinoma (chRCC, 5%). Each subtype is associated with a separate genetic syndrome, and therefore the treatment is also different.
  • ccRCC clear cell renal cell carcinoma
  • pRCC papillary renal cell carcinoma
  • chRCC pheochromocytic renal cell carcinoma
  • Clear cell renal cell carcinoma is the most common malignant tumor of the kidney, accounting for about 90% of renal cancer. According to the American Cancer Society, there are 403,000 new cases of renal cancer and 175,000 deaths worldwide each year; in China, there are about 66,800 new patients and 23,400 deaths each year. According to statistics from the National Cancer Spectrum of China, the incidence of kidney disease has increased at an average annual rate of 6.5% over the past 20 years, surpassing bladder cancer to rank first in urinary system tumor-related deaths. Kidney cancer can occur in people of all ages, with the high-incidence age mainly between 50 and 70 years old. Due to the relatively hidden location of the kidney and the lack of obvious clinical symptoms in the early stages of renal cancer, most renal cancer patients already have metastasis at the time of diagnosis.
  • renal cancer metastasizes (late stage), the prognosis is often poor, with a 5-year survival rate of less than 10%.
  • prostate cancer, bladder cancer, etc. it is not sensitive to radiotherapy and chemotherapy, which has become the biggest challenge in the treatment of renal cancer in the past. Therefore, it is a significant task to discover novel and confirmed specific drug targets for the treatment of renal cancer.
  • HIF Hypoxia-inducible factor
  • HIF family members include HIF-1 ⁇ , HIF-1 ⁇ , HIF-2 ⁇ , HIF-2 ⁇ , HIF-3 ⁇ , and HIF-3 ⁇ .
  • Abnormal HIF-2 ⁇ activity is a key carcinogenic driver of cancers such as clear cell renal cell carcinoma (ccRCC).
  • ccRCC clear cell renal cell carcinoma
  • PBDs prolyl hydroxylases
  • pVHL VHL complex
  • polyubiquitinate HIF-2 ⁇ mediate its degradation, so that HIF-2 ⁇ in the cell maintains a low expression level.
  • HIF-2 ⁇ Under hypoxic conditions, HIF-2 ⁇ cannot be hydroxylated, which makes it unable to recognize pVHL, so it accumulates and forms dimers with HIF-1 ⁇ , and then transfers to the nucleus, interacts with cofactors such as CBP/p300 and Pol II complex in the nucleus, and binds to HRE (hypoxia response element), thereby activating the expression of downstream target genes (VEGF-promotes angiogenesis; GLUT1 (glucose transporter-1)-activates glucose transport; LDHA (lactate dehydrogenase)-participates in the glycolysis pathway; and Epo-induces erythropoiesis, etc.).
  • VEGF-promotes angiogenesis VEGF-promotes angiogenesis
  • GLUT1 glucose transporter-1
  • LDHA lactate dehydrogenase
  • HIF-2 ⁇ inhibitors can treat/prevent diseases caused by overexpression of HIF-2 ⁇ , such as renal cell carcinoma.
  • Belzutifan (PT2977) is a HIF-2 ⁇ inhibitor approved by the U.S. FDA in 2021 for the treatment of adult patients with Hippel-Lindau syndrome.
  • the present invention provides a benzo[7]cycloolefin compound represented by the following formula (I) or a pharmaceutically acceptable salt, ester, optical isomer, tautomer, stereoisomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite, chelate, complex, inclusion compound or prodrug thereof,
  • Y 1 , Y 2 , Y 3 , Y 4 and Y 5 are each independently selected from CR 2 R 3 , NR 4 , CR 6 R 7 , NR 7 , S, O, SO 2 ; and at least one of Y 1 , Y 2 , Y 3 , Y 4 and Y 5 is CR 6 R 7 or NR 7 ; any two of R 2 to R 7 can be connected to form a substituted or unsubstituted C3-6 cycloalkyl, a substituted or unsubstituted 3-membered to 6-membered heterocycloalkyl;
  • the carbon-carbon bonds between Y 1 to Y 5 are schematic representations in the formula and can be single bonds or double bonds; as long as they form a ring according to reasonable stoichiometry,
  • W 1 , W 2 and W 3 are each independently selected from CR 5 or N, and W 4 is selected from CR 1 or N;
  • R 7 is a group represented by formula (a) or formula (b):
  • X1 is N, S or CR8a ;
  • X2 is N or CR8b ;
  • X3 is N or C, and when X3 is N, R11 is absent;
  • R8a and R8b are independently selected from one of H, halogen, CN, NO2 , C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 hydroxyalkyl, C1-4 alkoxyC1-4 alkyl, C3-6 cycloalkyl, -C(O)NRaRb, -S(O)2NRaRb and -S(O)2Ra;
  • R8b can form a substituted or unsubstituted C3-6 cycloalkyl , or a substituted or unsubstituted 3- to 6 - membered heterocycloalkyl with R11 ;
  • R9 and R10 are independently selected from the group consisting of H, halogen, CN, NO2 , C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 hydroxyalkyl, C1-6 hydroxyhaloalkyl, C1-4 alkoxyC1-4 alkyl, C3-8 cycloalkyl, -C(O)R a , -C(O)OR a , -C(O)NR a R b , -S(O) 2 NR a R b and -S(O) 2 R a ; each R a and R b are independently selected from the group consisting of H, C1-8 alkyl, C1-8 alkoxy, C1-8 haloalkyl, C1-8 haloalkoxy and C1-8 hydroxyalkyl,
  • R9 and R10 are combined to form a substituted or unsubstituted 5-membered carbocyclic or heterocyclic ring, a substituted or unsubstituted 6-membered carbocyclic or heterocyclic ring, or a heteroaryl ring,
  • R 11 is selected from the group consisting of H, halogen, CN, NO 2 , C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 hydroxyalkyl, C1-6 hydroxyhaloalkyl, C1-4 alkoxyC1-4 alkyl, C3-8 cycloalkyl, -POR c R b , -C(O)NR c R b , -N ⁇ S(O)R c R b , -N ⁇ S(O) 2 R b , -S(O) 2 NR c R b , -S(O)( ⁇ NR b )R c , -S(O) 2 R c , and a substituted or unsubstituted 5-membered or 6-membered heterocyclic or heteroaryl ring;
  • Ra and Rb are independently selected from one of H, C1-8 alkyl, C1-8 alkoxy, C1-8 haloalkyl, C1-8 haloalkoxy and C1-8 hydroxyalkyl;
  • Rc is selected from one of H, C1-8 alkyl, C1-8 alkoxy, C1-8 haloalkyl, C1-8 haloalkoxy, C1-8 hydroxyalkyl, substituted or unsubstituted C3-6 cycloalkyl, substituted or unsubstituted 3- to 6-membered heterocycloalkyl and substituted or unsubstituted 5- or 6-membered heteroaryl;
  • Rb and Rc may be connected to form a substituted or unsubstituted 3- to 6-membered heterocycloalkyl,
  • R10 and R11 are combined to form a substituted or unsubstituted 5-membered carbocyclic or heterocyclic ring, a substituted or unsubstituted 6-membered carbocyclic or heterocyclic ring, or a heteroaryl ring,
  • R 9 , R 10 and R 11 are combined to form a substituted or unsubstituted 9-11 membered carbocyclic or heterocyclic ring, or a heteroaryl ring,
  • connection site is any position on the ring structure that can form a bond.
  • the benzo[7]cycloolefin compound represented by formula (I) has a structure as described in the following formula (II) or formula (III):
  • R 11 , Y 2 , Y 3 , Y 4 , Y 5 , W 1 , W 2 , W 3 , and W 4 have the same meanings as in formula (I).
  • R9 and R10 are each independently selected from one of H, halogen, CN, NO2 , C1-6 alkyl, C1-6 haloalkyl, C1-6 alkoxy, C1-6 haloalkoxy, C1-6 hydroxyalkyl, C1-6 hydroxyhaloalkyl, C1-4 alkoxyC1-4 alkyl, C3-8 cycloalkyl, -C(O) Ra , -C(O) ORa , -C (O) NRaRb , -S(O) 2NRaRb and -S(O) 2Ra ;
  • n is an integer of 1 to 3
  • Ra and Rb is independently selected from H, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 haloalkoxy and C1-3 hydroxyalkyl.
  • the benzo[7]cycloolefin compound represented by formula (I) has a structure as described in the following formula (V):
  • R 11 , Y 2 , Y 3 , Y 4 , Y 5 , W 2 , W 3 , and W 4 have the same meanings as in formula (I).
  • R12 , R13 , R14 and R15 are each independently selected from one of H, halogen, CN, OH, C1-4 alkyl, C1-4 alkoxy and -NRaRb , and Ra and Rb are independently selected from one of H, C1-3 alkyl, C1-3 alkoxy, C1-3 haloalkyl, C1-3 haloalkoxy and C1-3 hydroxyalkyl.
  • R 11 is the following group Indicates the location of connection with the mother nucleus
  • W 2 and W 4 are -CHal- groups
  • Hal represents a halogen atom
  • at least one of R 12 , R 13 , R 14 and R 15 is a halogen atom.
  • the present invention also provides a pharmaceutical composition, comprising a preventive or therapeutically effective amount of a compound represented by formula (I) or a pharmaceutically acceptable salt, ester, optical isomer, stereoisomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite, chelate, complex, inclusion compound or prodrug thereof, and a pharmaceutically acceptable carrier.
  • the pharmaceutical composition is preferably a solid preparation, a semi-solid preparation, a liquid preparation or a gaseous preparation.
  • the dosage form of the pharmaceutical composition is an oral dosage form or an injection
  • the oral dosage form includes capsules, tablets, pills, powders and granules.
  • Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups or tinctures; the injection comprises a physiologically acceptable sterile aqueous or anhydrous solution, dispersion, suspension or emulsion, and a compound of the present invention or a pharmaceutically acceptable salt, ester, optical isomer, stereoisomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite, chelate, complex, inclusion compound or prodrug sterile powder for re-dissolving into a sterile injectable solution or dispersion.
  • the present invention provides the use of the above-mentioned compounds and pharmaceutical compositions for treating or preventing cancer, inflammatory diseases, and immune-related diseases. These diseases are closely related to type 2 ⁇ hypoxia-inducible factor, and regulating type 2 ⁇ hypoxia-inducible factor has therapeutic prospects for these diseases.
  • the cancer is the following cancer: prostate cancer, colon cancer, rectal cancer, pancreatic cancer, cervical cancer, gastric cancer, endometrial cancer, uterine cancer, brain cancer, liver cancer, bladder cancer, ovarian cancer, testicular cancer, head cancer, neck cancer, skin cancer (including melanoma and basal carcinoma), mesothelial cancer, leukocyte cancer, esophageal cancer, breast cancer, muscle cancer, connective tissue cancer, intestinal cancer, lung cancer, adrenal cancer, thyroid cancer, kidney or bone; glioblastoma cancer, mesothelioma cancer, renal cell carcinoma, clear cell renal cell carcinoma, gastric cancer, sarcoma, Kaposi's sarcoma, choriocarcinoma, basal cell carcinoma of the skin or testicular seminoma; the inflammation is selected from pneumonia, enteritis, nephritis, arthritis, traumatic infection; the metabolic disease is selected from obesity, dyslipidemia, hyperlipidemia.
  • the compounds of the present invention are particularly suitable for the treatment of renal cell carcinoma and clear cell renal cell carcinoma.
  • alkylene refers to a saturated divalent hydrocarbon group, preferably a saturated divalent hydrocarbon group having 1, 2, 3, 4, 5 or 6 carbon atoms, such as methylene, ethylene, propylene or butylene.
  • alkyl is defined as a linear or branched saturated aliphatic hydrocarbon. In some embodiments, the alkyl has 1 to 12, for example 1 to 6 carbon atoms.
  • C1-6 alkyl refers to a linear or branched group of 1 to 6 carbon atoms (e.g., methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl or n-hexyl), which is optionally substituted by 1 or more (such as 1 to 3) suitable substituents such as halogen (in this case, the group is referred to as " haloalkyl " ) (e.g., CH2F , CHF2 , CF3 , CCl3 , C2F
  • C1-4 alkyl refers to a linear or branched aliphatic hydrocarbon chain of 1 to 4 carbon atoms (ie, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl or tert-butyl).
  • alkenyl means a linear or branched monovalent hydrocarbon group containing one double bond and having 2 to 6 carbon atoms (“ C2-6 alkenyl”).
  • the alkenyl group is, for example, vinyl, 1-propenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2-methyl-2-propenyl and 4-methyl-3-pentenyl.
  • the compound of the present invention contains an alkenyl group, the compound may exist in the pure E (enthafen) form, the pure Z (zusammen) form or any mixture thereof.
  • alkynyl refers to a monovalent hydrocarbon group containing one or more triple bonds, preferably having 2, 3, 4, 5 or 6 carbon atoms, such as ethynyl or propynyl.
  • cycloalkyl refers to a saturated monocyclic or polycyclic (such as bicyclic) hydrocarbon ring (e.g., monocyclic, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, or bicyclic, including spirocyclic, fused or bridged systems (such as bicyclo[1.1.1]pentyl, bicyclo[2.2.1]heptyl, bicyclo[3.2.1]octyl or bicyclo[5.2.0]nonyl, decalinyl, etc.), which is optionally substituted with 1 or more (such as 1 to 3) suitable substituents.
  • monocyclic such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclonon
  • the cycloalkyl has 3 to 15 carbon atoms.
  • the so-called " C3-6 cycloalkyl” refers to a saturated monocyclic or polycyclic (such as bicyclic) hydrocarbon ring (e.g., cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl) of 3 to 6 ring-forming carbon atoms, which is optionally substituted with 1 or more (such as 1 to 3) suitable substituents, such as methyl-substituted cyclopropyl.
  • cycloalkylene group refers to a saturated (i.e., “cycloalkylene group” and “cycloalkyl group”) or unsaturated (i.e., having one or more double bonds and/or triple bonds within the ring) monocyclic or polycyclic hydrocarbon ring having, for example, 3-10 (suitably 3-8, more suitably 3-6) ring carbon atoms, including but not limited to (cyclo)propyl (ring), (cyclo)butyl (ring), (cyclo)pentyl (ring), (cyclo)hexyl (ring), (cyclo)heptyl (ring), (cyclo)octyl (ring), (cyclo)nonyl (ring), (cyclo)hexenyl (ring) and the like.
  • heterocyclyl As used herein, the so-called “heterocyclyl”, “heterocyclylene” and “heterocycle” refer to a saturated (i.e., heterocycloalkyl) or partially unsaturated (i.e., having one or more double bonds and/or triple bonds in the ring) cyclic group having, for example, 3-10 (suitably 3-8, more suitably 3-6) ring atoms, wherein at least one ring atom is a heteroatom selected from N, O and S and the remaining ring atoms are C.
  • a “3-10 membered (sub)heterocyclyl” is a saturated or partially unsaturated (sub)heterocyclyl having 2-9 (such as 2, 3, 4, 5, 6, 7, 8 or 9) ring carbon atoms and one or more (such as 1, 2, 3 or 4) heteroatoms independently selected from N, O and S.
  • cyclic and heterocyclic groups include, but are not limited to, oxiranyl, aziridine, azetidinyl, oxetanyl, tetrahydrofuranyl, dioxolinyl, pyrrolidinyl, pyrrolidonyl, imidazolidinyl, pyrazolidinyl, pyrrolinyl, tetrahydropyranyl, piperidinyl, morpholinyl, dithianyl, thiomorpholinyl, piperazinyl, or trithianyl.
  • the group also encompasses bicyclic systems including spiro, fused or bridged systems (such as 8-azaspiro [4.5] decane, 3,9-diazaspiro [5.5] undecane, 2-azabicyclo [2.2.2] octane, etc.).
  • the heterocyclylene and heterocyclyl groups may be optionally substituted with one or more (eg, 1, 2, 3 or 4) suitable substituents.
  • the so-called “(ylidene)aryl” and “aromatic ring” refer to an all-carbon monocyclic or fused-ring polycyclic aromatic group having a conjugated ⁇ electron system.
  • the so-called “C 6-10 (ylidene)aryl” and “C 6-10 aromatic ring” mean an aromatic group containing 6 to 10 carbon atoms, such as (ylidene)phenyl (benzene ring) or (ylidene)naphthyl (naphthalene ring).
  • the (ylidene)aryl and aromatic ring are optionally substituted with 1 or more (such as 1 to 3) suitable substituents (e.g., halogen, -OH, -CN, -NO 2 , C 1-6 alkyl, etc.).
  • suitable substituents e.g., halogen, -OH, -CN, -NO 2 , C 1-6 alkyl, etc.
  • heteroaryl(ene) and “heteroaromatic ring” refer to a monocyclic, bicyclic or tricyclic aromatic ring system having 5, 6, 8, 9, 10, 11, 12, 13 or 14 ring atoms, in particular 1 or 2 or 3 or 4 or 5 or 6 or 9 or 10 carbon atoms, and which contains at least one heteroatom which may be identical or different (the heteroatom being, for example, oxygen, nitrogen or sulfur) and, in each case additionally may be benzo-fused.
  • heteroaryl or “heteroaromatic ring” is selected from thiophenyl, furanyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, oxadiazolyl, triazolyl, thiadiazolyl, etc., and benzo derivatives thereof; or pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, etc., and benzo derivatives thereof.
  • aralkyl preferably refers to an alkyl substituted with an aryl or heteroaryl, wherein the aryl, heteroaryl and alkyl are as defined herein.
  • the aryl may have 6-14 carbon atoms
  • the heteroaryl may have 5-14 ring atoms
  • the alkyl may have 1-6 carbon atoms.
  • Exemplary aralkyls include, but are not limited to, benzyl, phenylethyl, phenylpropyl, phenylbutyl.
  • Alkyl refers to a saturated aliphatic hydrocarbon group, comprising 1-20 carbon atoms, or 1-10 carbon atoms, or 1-6 carbon atoms, or 1-4 carbon atoms, or 1-3 carbon atoms, or 1-2 carbon atoms, a saturated straight chain or branched monovalent hydrocarbon group, wherein the alkyl group may be independently optionally substituted with one or more substituents described herein.
  • alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1,1-dimethylpropyl, 1,2-dimethylpropyl, 2,2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1,1,2-trimethylpropyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 2,2-dimethylbutyl, 1,3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2,3-dimethylbutyl, etc.
  • the alkyl group may be optionally substituted or unsubstituted.
  • Alkenyl refers to a linear or branched monovalent hydrocarbon group of 2-12 carbon atoms, or 2-8 carbon atoms, or 2-6 carbon atoms, or 2-4 carbon atoms, wherein at least one CC is an sp2 double bond, wherein the alkenyl group may be independently optionally substituted with one or more substituents described herein, wherein specific examples include, but are not limited to, vinyl, allyl, and butylene, etc. Alkenyl may be optionally substituted or unsubstituted.
  • Cycloalkyl refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, the cycloalkyl ring includes 3 to 20 carbon atoms, preferably includes 3 to 12 carbon atoms, more preferably includes 3 to 6 carbon atoms.
  • Non-limiting examples of monocyclic cycloalkyl include, but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, etc.; polycyclic cycloalkyl includes cycloalkyl of spiro ring, condensed ring and bridge ring. Cycloalkyl can be optionally substituted or unsubstituted.
  • “Spirocycloalkyl” refers to a polycyclic group with 5 to 18 members, two or more cyclic structures, and one carbon atom (called spiro atom) shared between the monocyclic rings, containing one or more double bonds in the ring, but no ring has a completely conjugated ⁇ electron aromatic system. Preferably, it is 6 to 14 members, and more preferably 7 to 10 members.
  • the spirocycloalkyl is divided into single spiro, double spiro or multi-spirocycloalkyl, preferably single spiro and double spirocycloalkyl, preferably 4/5 members, 4/6 members, 5/5 members or 5/6 members.
  • spirocycloalkyl include, but are not limited to:
  • “Fused cycloalkyl” refers to a 5 to 18-membered, all-carbon polycyclic group containing two or more cyclic structures sharing a pair of carbon atoms, one or more rings may contain one or more double bonds, but no ring has a completely conjugated ⁇ electron aromatic system, preferably 6 to 12 members, more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic fused cycloalkyl, preferably bicyclic or tricyclic, more preferably 5-membered/5-membered or 5-membered/6-membered bicyclic alkyl.
  • Non-limiting examples of "fused cycloalkyl” include, but are not limited to:
  • Bridged cycloalkyl refers to a 5 to 18-membered, all-carbon polycyclic group containing two or more cyclic structures, sharing two carbon atoms that are not directly connected to each other, one or more rings may contain one or more double bonds, but no ring has a completely conjugated ⁇ electron aromatic system, preferably 6 to 12 members, more preferably 7 to 10 members. According to the number of constituent rings, it can be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl, preferably bicyclic, tricyclic or tetracyclic, more preferably bicyclic or tricyclic.
  • bridged cycloalkyl include, but are not limited to:
  • the cycloalkyl ring may be fused to an aryl, heteroaryl or heterocyclyl ring, wherein the ring attached to the parent structure is a cycloalkyl, non-limiting examples of which include indanyl, tetrahydronaphthyl, benzocycloheptanyl and the like.
  • Heterocyclyl “heterocycle” or “heterocyclic” are used interchangeably in this application and refer to a saturated or partially unsaturated monocyclic, bicyclic or tricyclic non-aromatic heterocyclic group containing 3-12 ring atoms, wherein at least one ring atom is a heteroatom, such as an oxygen, nitrogen, sulfur atom, etc. Preferably, it has a 5-7 membered monocyclic ring or a 7-10 membered bi- or tricyclic ring, which may contain 1, 2 or 3 atoms selected from nitrogen, oxygen and/or sulfur.
  • heterocyclyl examples include, but are not limited to, morpholinyl, oxetanyl, thiomorpholinyl, tetrahydropyranyl, 1,1-dioxo-thiomorpholinyl, piperidinyl, 2-oxo-piperidinyl, pyrrolidinyl, 2-oxo-pyrrolidinyl, piperazin-2-one, 8-oxa-3-aza-bicyclo[3.2.1]octyl and piperazinyl.
  • the heterocyclyl ring may be fused to an aryl, heteroaryl or cycloalkyl ring, wherein the ring attached to the parent structure is the heterocyclyl.
  • the heterocyclyl may be optionally substituted or unsubstituted.
  • spiro heterocyclyl is divided into single spiro heterocyclyl, double spiro heterocyclyl or multi-spiro heterocyclyl, preferably single spiro heterocyclyl and double spiro heterocyclyl. More preferably 4/4, 4/5, 4/6, 5/5 or 5/6 monospiro heterocyclyl.
  • spiro heterocyclyl include, but are not limited to:
  • the number of constituent rings it can be divided into a bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic group, preferably a bicyclic or tricyclic, more preferably a 5-membered/5-membered or 5-membered/6-membered bicyclic fused heterocyclic group.
  • fused heterocyclic group include, but are not limited to:
  • “Bridged heterocyclic group” refers to a polycyclic group of 5 to 18 members, containing two or more cyclic structures, sharing two atoms that are not directly connected to each other, one or more rings may contain one or more double bonds, but none of the rings has completely conjugated ⁇ electrons.
  • bridged heterocyclic groups include, but are not limited to:
  • Aryl refers to a carbocyclic aromatic system containing one or two rings, wherein the rings may be connected together in a fused manner.
  • the so-called “aryl” includes aromatic groups such as phenyl, naphthyl, and tetrahydronaphthyl.
  • the aryl is a C 6 -C 10 aryl, more preferably, the aryl is phenyl and naphthyl, and most preferably, phenyl.
  • the aryl may be substituted or unsubstituted.
  • the "aryl” may be fused with a heteroaryl, a heterocyclic group, or a cycloalkyl group, wherein the aryl ring is connected to the parent structure, and non-limiting examples include but are not limited to:
  • Heteroaryl refers to an aromatic 5 to 6-membered monocyclic or 9 to 10-membered bicyclic ring, which may contain 1 to 4 atoms selected from nitrogen, oxygen and/or sulfur.
  • the embodiment of “heteroaryl” includes, but is not limited to, furyl, pyridyl, 2-oxo-1,2-dihydropyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, thienyl, isoxazolyl, oxazolyl, oxadiazolyl, imidazolyl, pyrrolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, 1,2,3-thiadiazolyl, benzodioxolyl, benzimidazolyl, indolyl, isoindolyl, 1,3-dioxo-isoindolyl, quino
  • Heteroaryl may be optionally substituted or unsubstituted.
  • the heteroaryl ring may be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring connected to the parent structure is a heteroaryl ring, non-limiting examples include but are not limited to:
  • Alkoxy refers to a group of (alkyl-O-), wherein alkyl is as defined herein.
  • C 1 -C 6 alkoxy is preferred, and examples thereof include, but are not limited to, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, tert-butoxy, and the like.
  • Haloalkyl refers to an alkyl group having one or more halogen substituents, wherein the alkyl group has the meaning as described herein.
  • haloalkyl include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, perfluoroethyl, 1,1-dichloroethyl, 1,2-dichloropropyl, and the like.
  • Hydrophilicity refers to an -OH group.
  • Halogen refers to fluorine, chlorine, bromine and iodine, with fluorine, chlorine and bromine being preferred.
  • Amino refers to -NH2 .
  • Cyano refers to -CN.
  • Niro refers to -NO2 .
  • Benzyl refers to -CH2 -phenyl.
  • Carboxy refers to -C(O)OH.
  • Alcohol refers to -C(O) CH3 or Ac.
  • Carboxylate refers to -C(O)O(alkyl) or (cycloalkyl) wherein alkyl and cycloalkyl are as defined above.
  • halo or halogen groups are defined to include F, Cl, Br, or I.
  • substitution is meant that one or more (e.g., one, two, three, or four) hydrogen atoms on the designated atom are replaced by a selection from the indicated group, provided that the normal atomic valence of the designated atom in the present context is not exceeded and the substitution forms a stable compound. Combinations of substituents and/or variables are permitted only if such combinations form stable compounds.
  • substituent may be (1) unsubstituted or (2) substituted. If a carbon of a substituent is described as being optionally substituted with one or more of the listed substituents, then one or more hydrogens on the carbon (to the extent of any hydrogens present) may be replaced, individually and/or together, with independently selected optional substituents. If a nitrogen of a substituent is described as being optionally substituted with one or more of the listed substituents, then one or more hydrogens on the nitrogen (to the extent of any hydrogens present) may each be replaced with an independently selected optional substituent.
  • each substituent is selected independently of the other.
  • each substituent may be the same as or different from another (other) substituent.
  • one or more means 1 or more than 1, such as 2, 3, 4, 5 or 10, under reasonable conditions.
  • the point of attachment of a substituent may be from any suitable position of the substituent.
  • the present invention also includes all pharmaceutically acceptable isotopically labeled compounds, which are identical to the compounds of the present invention except that one or more atoms are replaced by atoms having the same atomic number but an atomic mass or mass number different from the atomic mass or mass number predominant in nature.
  • isotopes suitable for inclusion in the compounds of the present invention include, but are not limited to, isotopes of hydrogen (e.g., deuterium ( 2H ), tritium ( 3H )); isotopes of carbon (e.g., 11C , 13C , and 14C ); isotopes of chlorine (e.g., 36Cl ); isotopes of fluorine (e.g., 18F ); isotopes of iodine (e.g., 123I and 125I ); isotopes of nitrogen (e.g., 13N and 15N ); isotopes of oxygen (e.g., 15O , 17O , and 18O ); isotopes of phosphorus (e.g., 32P ); and isotopes of sulfur (e.g., 35S ).
  • isotopes of hydrogen e.g., deuterium ( 2H ), tritium ( 3H
  • Certain isotopically labeled compounds of the invention are useful in drug and/or substrate tissue distribution studies (e.g., assays).
  • the radioisotopes tritium (i.e., 3 H) and carbon-14 (i.e., 14 C) are particularly useful for this purpose because they are easily incorporated and easily detected.
  • Substitution with positron emitting isotopes e.g., 11 C, 18 F, 15 O, and 13 N
  • PET positron emission tomography
  • Isotopically labeled compounds of the invention can be prepared by methods similar to those described in the accompanying routes and/or examples and preparations by using appropriate isotopically labeled reagents in place of the non-labeled reagents previously employed.
  • Pharmaceutically acceptable solvates of the invention include those in which the crystallization solvent may be isotopically substituted, for example, D 2 O, acetone-d 6 or DMSO-d 6 .
  • Substituted means that one or more hydrogen atoms, preferably up to 5, more preferably 1-3 hydrogen atoms in the group are replaced independently of each other by a corresponding number of substituents. It goes without saying that the substituents are only in their possible chemical positions, and the person skilled in the art can determine (by experiment or theory) possible or impossible substitutions without undue effort. For example, amino or hydroxy groups with free hydrogens may be unstable when combined with carbon atoms with unsaturated (e.g. olefinic) bonds.
  • an "effective amount" of a compound refers to an amount sufficient to down-regulate or agonize a corresponding target.
  • the "therapeutically effective dose” of a compound refers to an amount sufficient to improve or in some way reduce symptoms, stop or reverse the progression of a disease, or negatively regulate or stimulate a corresponding target. This dose can be used as a single dose or taken according to a regimen to be effective.
  • treating means ameliorating or otherwise altering in any way the symptoms or pathology of a patient's condition, disorder or disease.
  • amelioration of the symptoms of a particular disease by administration of a particular compound or pharmaceutical composition refers to any reduction, whether permanent or temporary, lasting or transient, attributable to or associated with the administration of that composition.
  • the compounds of the present invention may contain asymmetric centers or chiral centers and therefore exist in different stereoisomers. All stereoisomeric forms of the compounds of the present invention, including but not limited to, diastereomers, enantiomers, atropisomers, and mixtures thereof, such as racemic mixtures, constitute part of the present invention.
  • Diastereoisomers can be separated into individual diastereomers on the basis of their physical chemical differences by methods such as chromatography, crystallization, distillation or sublimation.
  • Enantiomers can be separated to convert a chiral isomeric mixture into a diastereomeric mixture by reacting with an appropriate optically active compound (e.g., a chiral auxiliary such as a chiral alcohol or Mosher's acid chloride), separating the diastereomers, and converting the individual diastereomers into the corresponding pure enantiomers.
  • an appropriate optically active compound e.g., a chiral auxiliary such as a chiral alcohol or Mosher's acid chloride
  • the intermediates and compounds of the present invention may also exist in different tautomeric forms, and all such forms are included within the scope of the present invention.
  • optically active forms i.e., they have the ability to rotate the plane of plane polarized light.
  • the prefixes D, L or R, S are used to indicate the absolute configuration of the chiral center of the molecule.
  • the prefixes d, l or (+), (-) are used to name the sign of rotation of the plane of polarized light of the compound, (-) or l means that the compound is left-handed, and the prefix (+) or d means that the compound is right-handed.
  • These stereoisomers have the same order of attachment of atoms or groups of atoms to each other, but their stereostructures are different.
  • Stereoisomers may be enantiomers, and mixtures of isomers are usually called enantiomeric mixtures.
  • a 50:50 mixture of enantiomers is called a racemic mixture or racemate, which may result in no stereoselectivity or stereospecificity during chemical reactions.
  • the so-called “racemic mixture” and “racemate” refer to an equimolar mixture of two enantiomers that lacks optical activity.
  • Tautomers or “tautomeric forms” refer to structural isomers of different energies that can be interconverted through a low energy barrier.
  • proton tautomers i.e., prototropic tautomers
  • Valence (chemical valence) tautomers include interconversions by reorganization of bonding electrons.
  • the structural formulas described in the present invention include all isomeric forms (such as enantiomers, diastereomers, and geometric isomers): for example, R, S configurations containing asymmetric centers, (Z), (E) isomers of double bonds, and (Z), (E) conformational isomers. Therefore, single stereochemical isomers of the compounds of the present invention or mixtures of their enantiomers, diastereomers, or geometric isomers are all within the scope of the present invention.
  • “Pharmaceutically acceptable salts” refer to salts of the compounds of the present invention, which are safe and effective when used in humans or animals. Salts of compounds can be obtained by using a sufficient amount of base or acid in a pure solution or a suitable inert solvent to obtain the corresponding addition salt.
  • Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amino or magnesium salts, etc.
  • pharmaceutically acceptable acid addition salts include inorganic acid salts and organic acid salts.
  • the inorganic and organic acids include hydrochloric acid, hydrobromic acid, carbonic acid, bicarbonate, phosphoric acid, monohydrogen phosphate, dihydrogen phosphate, sulfuric acid, monohydrogen sulfate, acetic acid, maleic acid, malonic acid, succinic acid, butenedioic acid, phthalic acid, benzenesulfonic acid, p-toluenesulfonic acid, citric acid and methanesulfonic acid, etc. (see Berge et al., "Pharmaceutical Salts", Journal of Pharmaceutical Science 66: 1-19 (1977)).
  • solid lines can be used Solid wedge Virtual wedge Depicting chemical bonds of the compounds of the invention.
  • the use of solid lines to depict bonds to asymmetric carbon atoms is intended to indicate that all possible stereoisomers at that carbon atom are included (e.g., specific enantiomers, racemic mixtures, etc.).
  • the use of solid or dashed wedges to depict bonds to asymmetric carbon atoms is intended to indicate that the stereoisomer shown is present. When present in a racemic mixture, the solid and dashed wedges are used to define relative stereochemistry, not absolute stereochemistry.
  • the compounds of the invention are intended to exist in the form of stereoisomers, which include cis and trans isomers, optical isomers (e.g., R and S enantiomers), diastereomers, geometric isomers, rotational isomers, conformational isomers, atropisomers, and mixtures thereof.
  • the compounds of the invention may exhibit more than one type of isomerism and consist of mixtures thereof (e.g., racemic mixtures and diastereomeric pairs).
  • the present invention encompasses all possible crystalline forms or polymorphs of the compounds of the present invention, which may be a single polymorph or a mixture of more than one polymorph in any ratio.
  • compositions of the present invention may exist in free form for treatment, or, where appropriate, in the form of pharmaceutically acceptable derivatives thereof.
  • pharmaceutically acceptable derivatives include, but are not limited to, pharmaceutically acceptable salts, esters, solvates, N-oxides, metabolites, chelates, complexes, inclusion compounds or prodrugs, which, after being administered to a patient in need thereof, can directly or indirectly provide a compound of the present invention or a metabolite or residue thereof. Therefore, when referring to "compounds of the present invention” herein, it is also intended to cover the above-mentioned various derivative forms of the compound.
  • Pharmaceutically acceptable salts of the compounds of the present invention include acid addition salts and base addition salts thereof, including but not limited to those containing hydrogen bonds or Salts with coordinated bonds.
  • Suitable acid addition salts are formed from acids which form pharmaceutically acceptable salts. Examples include acetate, adipate, aspartate, benzoate, benzenesulfonate, bicarbonate/carbonate, bisulfate/sulfate, borate, camphorsulfonate, citrate, cyclamate, edisylate, ethanesulfonate, formate, fumarate, glucoheptonate, gluconate, glucuronate, hexafluorophosphate, hyaluronate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, methanesulfonate, methylsulfate, naphthylate, 2-naphthalenesulfonate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate,
  • Suitable base addition salts are formed with bases which form pharmaceutically acceptable salts.
  • bases include aluminum, arginine, benzathine, calcium, choline, diethylamine, diethanolamine, glycine, lysine, magnesium, meglumine, ethanolamine, potassium, sodium, tromethamine, and zinc salts.
  • esters refers to esters derived from the compounds of the general formulae herein, including physiologically hydrolyzable esters (which can be hydrolyzed under physiological conditions to release the compounds of the present invention in free acid or alcohol form).
  • physiologically hydrolyzable esters which can be hydrolyzed under physiological conditions to release the compounds of the present invention in free acid or alcohol form.
  • the compounds of the present invention themselves may also be esters.
  • the compounds of the present invention may exist in the form of solvates (preferably hydrates), wherein the compounds of the present invention contain polar solvents as structural elements of the crystal lattice of the compounds, in particular water, methanol or ethanol.
  • polar solvents as structural elements of the crystal lattice of the compounds, in particular water, methanol or ethanol.
  • the amount of polar solvents, in particular water may exist in a stoichiometric or non-stoichiometric ratio.
  • nitrogen-containing heterocycles are capable of forming N-oxides, as nitrogen requires an available lone pair of electrons to oxidize to an oxide; those skilled in the art will recognize nitrogen-containing heterocycles that are capable of forming N-oxides. Those skilled in the art will also recognize that tertiary amines are capable of forming N-oxides.
  • Synthetic methods for preparing N-oxides of heterocycles and tertiary amines are well known to those skilled in the art, including oxidation of heterocycles and tertiary amines with peroxyacids such as peracetic acid and meta-chloroperbenzoic acid (MCPBA), hydrogen peroxide, alkyl hydroperoxides such as tert-butyl hydroperoxide, sodium perborate, and dioxirane such as dimethyldioxirane.
  • peroxyacids such as peracetic acid and meta-chloroperbenzoic acid (MCPBA)
  • hydrogen peroxide alkyl hydroperoxides such as tert-butyl hydroperoxide
  • sodium perborate sodium perborate
  • dioxirane such as dimethyldioxirane
  • metabolites of the compounds of the present invention i.e., substances formed in vivo upon administration of the compounds of the present invention. Such products may be produced, for example, by oxidation, reduction, hydrolysis, amidation, deamidation, esterification, enzymatic hydrolysis, etc. of the administered compound.
  • the present invention includes metabolites of the compounds of the present invention, including compounds prepared by contacting the compounds of the present invention with a mammal for a period of time sufficient to produce a metabolic product thereof.
  • the present invention further includes within its scope prodrugs of the compounds of the present invention, which are certain derivatives of the compounds of the present invention that may themselves have less pharmacological activity or no pharmacological activity, which when administered into or onto the body can be converted into compounds of the present invention having the desired activity by, for example, hydrolytic cleavage.
  • prodrugs will be functional group derivatives of the compounds that are easily converted into the desired therapeutically active compounds in vivo. Additional information on the use of prodrugs can be found in "Pro-drugs as Novel Delivery Systems", Vol. 14, ACS Symposium Series (T. Higuchi and V. Stella).
  • Prodrugs of the present invention can be prepared, for example, by replacing appropriate functional groups present in the compounds of the present invention with certain moieties known to those skilled in the art as "pro-moieties” (e.g., as described in “Design of Prodrugs", H. Bundgaard (Elsevier, 1985)).
  • the present invention also encompasses compounds of the present invention containing protecting groups.
  • protecting groups In any process for preparing the compounds of the present invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules involved, thereby forming a chemically protected form of the compounds of the present invention. This can be achieved by conventional protecting groups, for example, those described in T.W.Greene & P.G.M.Wuts, Protective Groups in Organic Synthesis, John Wiley & Sons, 1991, which references are incorporated herein by reference. Protecting groups may be removed at an appropriate subsequent stage using methods known in the art.
  • the present invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising an effective amount of a compound of the present invention or a pharmaceutically acceptable salt, ester, optical isomer, stereoisomer, polymorph, solvate, N-oxide, isotope-labeled compound, metabolite, chelate, complex, inclusion compound or prodrug thereof, and a pharmaceutically acceptable carrier.
  • the pharmaceutical composition is preferably a solid preparation, a semisolid preparation, a liquid preparation or a gaseous preparation.
  • pharmaceutically acceptable carrier refers to a diluent, adjuvant, excipient or vehicle that is administered together with a therapeutic agent and is suitable for contact with the tissues of humans and/or other animals without excessive toxicity, irritation, allergic reaction or other problems or complications corresponding to a reasonable benefit/risk ratio within the scope of reasonable medical judgment.
  • Pharmaceutically acceptable carriers that can be used in the pharmaceutical compositions of the present invention include, but are not limited to, sterile liquids, such as water and oils, including those of petroleum, animal, plant or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like.
  • sterile liquids such as water and oils, including those of petroleum, animal, plant or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, and the like.
  • water is an exemplary carrier.
  • Physiological saline and aqueous solutions of glucose and glycerol can also be used as liquid carriers, particularly for injections.
  • Suitable pharmaceutical excipients include starch, glucose, lactose, sucrose, gelatin, maltose, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, skim milk powder, glycerol, propylene glycol, water, ethanol, and the like.
  • the composition may also contain a small amount of a wetting agent, emulsifier, or pH buffer as desired.
  • Oral preparations may contain standard carriers, such as pharmaceutical grade mannitol, lactose, starch, magnesium stearate, sodium saccharin, cellulose, magnesium carbonate, and the like. Examples of suitable pharmaceutically acceptable carriers are described in Remington’s Pharmaceutical Sciences (1990).
  • compositions of the present invention can act systemically and/or locally.
  • they can be administered by suitable routes, for example by injection (such as intravenous, intraarterial, subcutaneous, intraperitoneal, intramuscular injection, including instillation) or transdermal administration; or by oral, buccal, nasal, transmucosal, local, in the form of ophthalmic preparations or by inhalation.
  • suitable routes for example by injection (such as intravenous, intraarterial, subcutaneous, intraperitoneal, intramuscular injection, including instillation) or transdermal administration; or by oral, buccal, nasal, transmucosal, local, in the form of ophthalmic preparations or by inhalation.
  • the pharmaceutical composition of the present invention can be administered in suitable dosage forms.
  • the dosage forms include, but are not limited to, tablets, capsules, lozenges, hard candies, powders, sprays, creams, ointments, suppositories, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, and syrups.
  • the pharmaceutical composition of the present invention can be used to prevent and/or treat pain.
  • other pain treatment agents such as fluoxetine, opioid analgesics, non-opioid analgesics, etc. can also be used simultaneously.
  • the pharmaceutical composition of the present invention contains a safe and effective amount of the compound of the present invention and a pharmaceutically acceptable carrier or excipient.
  • a pharmaceutically acceptable carrier or excipient include (but are not limited to): one or more of saline, buffer, glucose, water, glycerol, ethanol, powder, etc.
  • the pharmaceutical preparation should match the administration method.
  • the pharmaceutical composition of the present invention can be prepared in the form of an injection, for example, by conventional methods using physiological saline or an aqueous solution containing glucose and other adjuvants.
  • Pharmaceutical compositions such as tablets and capsules can be prepared by conventional methods.
  • Pharmaceutical compositions such as injections, solutions, tablets and capsules are preferably manufactured under aseptic conditions.
  • the pharmaceutical composition of the present invention can also be prepared in powder form for aerosol inhalation.
  • the dosage of the active ingredient is a therapeutically effective amount, for example, about 1 ⁇ g/kg body weight to about 50 mg/kg body weight per day; preferably, about 5 ⁇ g/kg body weight to about 10 mg/kg body weight; further preferably, about 10 ⁇ g/kg body weight to about 5 mg/kg body weight.
  • the compounds of the present invention can also be used together with other therapeutic agents.
  • composition of the present invention can be administered to a desired subject (such as a human or non-human mammal) in a conventional manner, and representative administration methods include (but are not limited to): oral administration, injection, aerosol inhalation, and the like.
  • a safe and effective amount of the drug is administered to a mammal, wherein the safe and effective amount is usually at least about 10 micrograms/kg body weight, and in most cases does not exceed about 50 milligrams/kg body weight, preferably, the dose is about 10 micrograms/kg body weight to about 20 milligrams/kg body weight.
  • the specific dose should also take into account factors such as the route of administration and the patient's health status, which are all within the skill of a skilled physician.
  • the so-called “effective amount” refers to the amount of the compound that, after being administered, will alleviate one or more symptoms of the treated condition to a certain extent. Specifically, as used herein, the “effective amount” of the compound refers to an amount sufficient to inhibit type 2 ⁇ hypoxia-inducible factor or inhibit cancer. As used herein, the “therapeutically effective dose” of the compound refers to an amount sufficient to improve or reduce symptoms in some way, stop or reverse the progression of the disease, or inhibit type 2 ⁇ hypoxia-inducible factor. This dose can be used as a single dose or taken according to a regimen, so as to be effective.
  • the dosage regimen may be adjusted to provide the best desired response. For example, a single bolus may be administered, several divided doses may be administered over time, or the dosage may be proportionally reduced or increased as indicated by the urgency of the therapeutic situation. It is noted that dosage values may vary with the type and severity of the condition to be alleviated, and may include single or multiple doses. It is further understood that for any particular individual, the specific dosage regimen should be adjusted over time according to the individual's needs and the professional judgment of the person administering or supervising the administration of the composition.
  • treat means to ameliorate or otherwise modify in any way the symptoms or pathology of a patient's condition, disorder or disease.
  • “ameliorating the symptoms of a particular disease by the use of a particular compound or pharmaceutical composition” means any reduction, whether permanent or temporary, lasting or temporary, attributable to or associated with the use of the composition.
  • “individual” includes human or non-human animals.
  • Exemplary human individuals include human individuals (referred to as patients) suffering from diseases (e.g., diseases described herein) or normal individuals.
  • Non-human animals in the present invention include all vertebrates, such as non-mammals (e.g., birds, amphibians, reptiles) and mammals, such as non-human primates, livestock and/or domesticated animals (e.g., sheep, dogs, cats, cows, pigs, etc.).
  • An important aspect of the present invention is to provide the use of the above-mentioned benzo[7]cycloolefin derivatives provided by the present invention in the preparation of a drug for treating a disease selected from cancer, inflammation, and metabolic diseases
  • a disease selected from cancer, inflammation, and metabolic diseases
  • the cancer is selected from cancer of the head, neck, eye, mouth, throat, esophagus, bronchus, larynx, pharynx, chest, bone, lung, colon, rectum, stomach, prostate, bladder, uterus, cervix, breast, ovary, testis or other reproductive organs, skin, thyroid, blood, lymph node, kidney, liver, pancreas, brain, central nervous system, solid tumors and hematogenous tumors, glioblastoma, renal cell carcinoma (RCC) and clear cell renal cell carcinoma (ccRCC);
  • the inflammation is selected from pneumonia, enteritis, nephritis, arthritis, and traumatic infection
  • the metabolic disease is
  • the present invention also provides a method for treating cancer using benzo[7]cyclopentane derivatives as inhibitors, which is carried out by administering an effective amount of the compound to a subject suffering from cancer.
  • the so-called “effective amount” means an amount of a compound or composition sufficient to significantly and positively alter the symptoms and/or condition to be treated (e.g., provide a positive clinical response).
  • the effective amount of the active ingredient used in a pharmaceutical composition will vary with the specific condition being treated, the severity of the condition, the duration of treatment, the nature of concurrent treatment, the specific active ingredient(s) used, the pharmaceutically acceptable excipient(s)/carrier(s) used, and similar factors within the knowledge and expertise of the attending physician.
  • an effective amount of a compound of formula (I) for use in cancer treatment is an amount sufficient to symptomatically alleviate the symptoms of cancer in humans, to slow the progression of cancer, or to reduce the risk of worsening symptoms in patients with cancer.
  • the pharmaceutical composition of the present invention may also include one or more additional therapeutic or preventive agents.
  • the mass spectrum was obtained by LC/MS using ESI as the ionization method.
  • HPLC model Agilent 1260, Thermo Fisher U3000; chromatographic column model: Waters xbrige C18 (4.6*150 mm, 3.5 ⁇ m); mobile phase: A: ACN, B: Water (0.1% H 3 PO 4 ); flow rate: 1.0 mL/min; gradient: 5% A for 1 min, increase to 20% A within 4 min, increase to 80% A within 8 min, 80% A for 2 min, back to 5% A within 0.1 min; wavelength: 220 nm; column oven: 35°C.
  • the thin layer chromatography silica gel plate uses Yantai Huanghai HSGF254 or Qingdao GF254 silica gel plate.
  • the silica gel plate used in thin layer chromatography (TLC) adopts a specification of 0.2mm-0.3mm, and the specification used for thin layer chromatography separation and purification products is 0.4mm-0.5mm.
  • R f The ratio of the distance from the origin to the center of the spot to the distance from the origin to the solvent front in thin layer chromatography.
  • Hydrogen atmosphere means that the reaction bottle is connected to a hydrogen balloon with a volume of about 1L.
  • the solution in the reaction refers to an aqueous solution.
  • reaction temperature is room temperature, 20°C-30°C.
  • the reaction progress in the embodiment is monitored by thin layer chromatography (TLC), and the developing solvent used in the reaction, the eluent system of column chromatography or the developing solvent system of thin layer chromatography used for purifying the compound includes: A: petroleum ether and ethyl acetate system; B: dichloromethane and methanol system; C: n-hexane: ethyl acetate; wherein the volume ratio of the solvent varies according to the polarity of the compound, and a small amount of acidic or alkaline reagent, such as acetic acid or triethylamine, can also be added for adjustment.
  • TLC thin layer chromatography
  • Step 7 4-bromo-7-trifluoromethylsulfonyl-2,3-dihydro-1H-inden-1-one IN-1h
  • Step 8 4-bromo-2-fluoro-7-trifluoromethylsulfonyl-2,3-dihydro-1H-inden-1-one IN-1i
  • reaction solution was cooled to room temperature, diluted with methyl tert-butyl ether (20 mL), filtered, and the filter cake was washed twice with methyl tert-butyl ether (20 mL).
  • reaction solution was quenched by adding saturated sodium bicarbonate solution (20 mL), extracted with dichloromethane (20 mL x 2), and the organic phases were combined. The residue was washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and concentrated.
  • the crude product was purified by silica gel column chromatography to obtain the title compound IN-1 (0.307 g, yield 64%) as a white solid.
  • the first step 4-bromo-7-(methylthio)-2,3-dihydro-1H-inden-1-one IN-2b
  • the reaction solution was added with sodium sulfite aqueous solution (60 mL), filtered, and the filter cake was washed with ethyl acetate (120 mL x 2).
  • the filtrate was filtered with diatomaceous earth pad, washed with water (60 mL), washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, and concentrated to obtain the title compound IN-2c (12.2 g, yield: 98.6%) as a white solid.
  • Step 4 (1S, 2R)-2-fluoro-7-(methylsulfonyl)-4-bromo-2,3-dihydro-1H-indene 1-ol IN-2e
  • the reaction solution was cooled to room temperature, diluted with ethyl acetate (4 mL), filtered through diatomaceous earth, and the filter cake was washed with ethyl acetate (6 mL), the filtrate was washed with water (4 mL), washed with saturated brine (4 mL), dried over anhydrous sodium sulfate, and concentrated to obtain a crude product.
  • Step 5 2-(1,3-difluoro-6,7-dihydro-5H-benzo[7]cycloalken-9-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborane 1f
  • Step 6 (1S, 2R)-4-(1,3-difluoro-6,7-dihydro-5H-benzo[7]cycloalkene-9-yl)-2-fluoro-7-((trifluoromethyl)sulfonyl)-2,3-dihydro-1H-inden-1-ol 1g
  • the reaction solution was cooled to 28°C, the reaction was quenched, and ethyl acetate (10 mL x 2) was used for extraction.
  • the organic phases were combined, washed with water (10 mL), dried over anhydrous sodium sulfate, and concentrated.
  • Step 7 (1S,2R)-4-((R)-2,4-difluoro-6,7,8,9-tetrahydro-5H-benzo[7]cycloalken-5-yl)-2-fluoro-7-((trifluoromethyl)sulfonyl)-2,3-dihydro-1H-inden-1-ol 1
  • 6,8-difluoro-3,4-dihydronaphthalene-1(2H)-one 2a (2.0 g, 10.98 mmol) was dissolved in a mixed solution of ethanol (20 mL)/water (7 mL), and hydroxylamine hydrochloride (1.1 g, 16.47 mmol) and sodium acetate (1.4 g, 16.47 mmol) were added in sequence. After the addition, the reaction solution was reacted at room temperature for 3 hours, and solids precipitated.
  • the reaction solution is cooled to room temperature, ice water (10 mL) is added and stirred in an ice bath for 30 minutes. Filter by suction, and filter cake column chromatography to obtain the light yellow solid title compound 2d (624 mg, yield 69%).
  • Step 5 6-(7,9-difluoro-2,3,4,5-tetrahydro-1H-benzo[b]azepin-1-yl)-2-fluoro-3-(trifluoromethyl)benzonitrile 2
  • reaction solution was cooled to room temperature, quenched with water (10 mL), and extracted with ethyl acetate (10 mL). Washed with saturated brine (10 mL) and concentrated.
  • the reaction solution was cooled to room temperature, 1N dilute hydrochloric acid (10 mL) was added to adjust the pH to 2-3, and ethyl acetate (100 mL x 2) was used for extraction.
  • the organic phases were combined, washed with saturated brine (100 mL), dried over anhydrous sodium sulfate, and concentrated.
  • Step 4 4-(1,3-difluoro-6,7-dihydro-5H-benzo[7]cycloalken-9-yl)-7-[(dimethyl(oxo)-sulfylinyl)amino]-2,3-dihydro-1H-inden-one 3e
  • reaction solution was filtered through diatomaceous earth, diluted with ethyl acetate (50mL), washed twice with saturated brine (50mL), and the organic phase was dried and concentrated.
  • Step 5 4-(1,3-difluoro-6,7-dihydro-5H-benzo[7]cycloalken-9-yl)-7-[(dimethyl(oxo)-sulfylinyl)amino]-2-fluoro-2,3-dihydro-1H-inden-1-one 3f
  • Step 6 ((2R,3S)-7-(1,3-difluoro-6,7-dihydro-5H-benzo[7]cycloolefin-9-yl)-2-fluoro-3-hydroxy-2,3-dihydro-1H-inden-4-yl)imino)dimethyl-sulfone ketone sulfone 3g
  • Step 7 (((2R,3S)-7-((R)-2,4-difluoro-6,7,8,9-tetrahydro-5H-benzo[7]cycloalken-5-yl)-2-fluoro-3-hydroxy-2,3-dihydro-1H-inden-4-yl)imino)dimethyl- ⁇ 6 -sulfonamide 3
  • Tetramethylene sulfoxide 4a (1.00 g, 9.60 mmol) was dissolved in methanol (40 mL), cooled to 0°C, and iodophenyl diacetic acid (9.28 g, 28.80 mmol) and ammonium carbamate (3.00 g, 38.43 mmol) were added. After the addition was completed, the reaction solution was slowly returned to room temperature to react for 1 hour.
  • Step 2 4-(1,3-difluoro-6,7-dihydro-5H-benzo[7]cycloalken-9-yl)-7-((1-oxytetrahydro-thiophen-1-ylidene)amino)-2,3-dihydro-1H-inden-1-one 4c
  • Step 3 4-(1,3-difluoro-6,7-dihydro-5H-benzo[7]cycloalken-9-yl)-2-fluoro-7-((1-oxytetrahydro-thiophen-1-ylidene)amino)-2,3-dihydro-1H-inden-1-one 4d
  • Step 4 1-((2R,3S)-7-(1,3-difluoro-6,7-dihydro-5H-benzo[7]cycloalken-9-yl)-2-fluoro-3-hydroxy-2,3-dihydro-1H-indol-4-yl)imine)tetrahydro-1H-thiophene-1-oxide 4e
  • the reaction was quenched by adding saturated sodium bicarbonate solution (10 mL), extracted with dichloromethane (10 mL x 2), and the organic phases were combined, washed with water (10 mL), dried over anhydrous sodium sulfate, and concentrated.
  • Step 5 1-((2R,3S)-7-((R)-2,4-difluoro-6,7,8,9-tetrahydro-5H-benzo[7]cycloalken-5-yl)-2-fluoro-3-hydroxy-2,3-dihydro-1H-inden-4-yl)imino)tetrahydro-1H-1 ⁇ 6 -thiophene-1-oxide 4
  • Step 1 2-Fluoro-4-methoxy-6,7,8,9-tetrahydro-5H-benzo[7]cycloalkene-5-one, 2-fluoro-4-hexyloxy-6,7,8,9-tetrahydro-5H-benzo[7]cycloalkene-5-one and 2-fluoro-4-hydroxy-6,7,8,9-tetrahydro-5H-benzo[7]cycloalkene-5-one mixture 5a
  • Disperse compound 1d (4.5 g, 22.9 mmol) in 1,4-dioxane (60 mL), add sodium trimethylsilanol (7.7 g, 68.8 mmol), replace with nitrogen several times, and heat the reaction solution to 90 ° C and stir for 3 hours.
  • reaction solution is cooled to room temperature, quenched with water (50 mL), extracted with ethyl acetate (80 mL x 3), combined with organic phases, washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, and concentrated to obtain the title compound 5a (5.6 g, crude product) as a brown oil, which is directly used in the next step.
  • the reaction solution was cooled to room temperature, quenched with water (60 mL), extracted with ethyl acetate (80 mL x 2), and the organic phases were combined, washed with water (60 mL x 3), washed with saturated brine (60 mL), dried over anhydrous sodium sulfate, and concentrated to obtain a crude product.
  • the reaction solution was cooled to room temperature, quenched with water (50 mL), extracted with dichloromethane (60 mL x 2), and the organic phases were combined and washed with saturated brine (50 mL).
  • the crude product was dried over anhydrous sodium sulfate and concentrated.
  • the reaction solution was cooled to room temperature, quenched with water (50 mL), extracted with ethyl acetate (80 mL x 2), and the organic phases were combined, washed with saturated brine (50 mL x 3), dried over anhydrous sodium sulfate, and concentrated.
  • Step 6 3-Fluoro-9-((1S,2R)-2-fluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)-6,7-dihydro-5H-benzo[7]cycloolefin-1-carbonitrile 5
  • the reaction solution was cooled to room temperature, quenched with water (3 mL), extracted with ethyl acetate (5 mL x 2), and the organic phases were combined, washed with saturated brine (3 mL), dried over anhydrous sodium sulfate, and concentrated to obtain a crude product.
  • the crude product was prepared and purified to obtain the title compound 5 (35 mg, yield: 34.4%) as a white solid.
  • Step 1 (1S,2R)-4-(1,3-difluoro-6,7-dihydro-5H-benzo[7]cycloen-9-yl)-2-fluoro-7-(methylsulfonyl)-2,3-dihydro-1H-inden-1-ol 6a
  • reaction solution was cooled to room temperature, quenched with water, extracted with ethyl acetate (10 mL x 2), the organic phases were combined, washed with water (10 mL), dried over anhydrous sodium sulfate, and concentrated.
  • reaction solution was poured into ice water (100 mL) for quenching, extracted with ethyl acetate (100 mL x 2), the organic phases were combined, dried over anhydrous sodium sulfate, and concentrated.
  • the reaction mixture was cooled to room temperature, diluted with water (3 mL), extracted with ethyl acetate (5 mL x 2), and the organic phases were combined, washed with saturated brine (3 mL), dried over anhydrous sodium sulfate, and concentrated to obtain a crude product.
  • Step 5 Tert-butyl ((1,3-dichloro-5-fluoro-4H-cyclopenta[c]thiophen-6-yl)oxy) dimethylsilane 8f
  • Step 7 1-Chloro-5,5-difluoro-3-(methylthio)-5,6-dihydro-4H-cyclopenta[c]thiophene-4-one 8h
  • Step 8 1-Chloro-5,5-difluoro-3-(methylsulfonyl)-5,6-dihydro-4H-cyclopenta[c]thiophene-4-one 8i
  • Step 9 1-Chloro-5,5-difluoro-3-(methylsulfonyl)-5,6-dihydrospiro[cyclopenta[c]thiophene-4,2'-[1,3]dioxolane]8j
  • N,N-dimethylformamide (15 mL), potassium carbonate (1.01 g, 7.26 mmol) and 2-bromoethane-1-ol (924 mg, 7.02 mmol) were added to compound 8i (1.1 g, 3.45 mmol) in a 100 mL round-bottom flask at room temperature. The resulting mixture was stirred at room temperature for 2 h. It was then diluted with 100 mL of ethyl acetate and washed with water (3 ⁇ 50 mL). The organic phase was dried over sodium sulfate and concentrated under reduced pressure. The residue was purified by column chromatography eluting with (PE/EA 3:1) to give the title compound 8j (light yellow solid, 0.95 g).
  • Step 10 1-(1,3-difluoro-6,7-dihydro-5H-benzo[7]cycloalken-9-yl)-5,5-difluoro-3-(methylsulfonyl)-5,6-dihydrospiro[cyclopenta[c]thiophene-4,2'-[1,3]dioxolane]8k
  • Step 11 1-(1,3-difluoro-6,7-dihydro-5H-benzo[7]cycloalken-9-yl)-5,5-difluoro-3-(methylsulfonyl)-5,6-dihydro-4H-cyclopenta[c]thiophen-4-one 81
  • Step 12 (S)-1-(1,3-difluoro-6,7-dihydro-5H-benzo[7]cycloalken-9-yl)-5,5-difluoro-3-(methylsulfonyl)-5,6-dihydro-4H-cyclopenta[c]thiophen-4-ol 8m
  • Step 13 (S)-1-((S)-2,4-difluoro-6,7,8,9-tetrahydro-5H-benzo[7]cycloalken-5-yl)-5,5-difluoro-3-(methylsulfonyl)-5,6-dihydro-4H-cyclopentyl[c]thiophen-4-ol 8
  • compound 8m (60 mg, 0.14 mmol) was dissolved in methanol (5 ml) and palladium carbon (6 mg, 10% w) was added. The mixture was reacted for 14 h under hydrogen atmosphere. The mixture was filtered through diatomaceous earth and the filtrate was directly dried by spin drying and purified by Prep-TLC to obtain the title compound 8 (yellow solid, 0.03 g).
  • N-iodosuccinimide (16 mg, 0.070 mmol) and pyridine hydrofluoride (25 mg, 0.18 mmol) were dissolved in dichloromethane (0.5 mL), cooled to -60 °C, and a mixture of compound 9c (19 mg, 0.035 mmol) and dichloromethane (0.2 mL) was slowly added dropwise. After addition, the mixture was allowed to react at -60 °C for 0.5 h. TLC showed that the reaction of the raw material was complete. Water (10 mL) was added to quench the reaction, and ethyl acetate (5 mL x 2) was used for extraction.
  • Step 1 3-Fluoro-9-((1S,2R)-2-fluoro-1-hydroxy-7-((trifluoromethyl)sulfonyl)-2,3-dihydro-1H-inden-4-yl)-6,7-dihydro-5H-benzo[7]naphthylidene-1-carbonitrile 10a
  • Step 2 (R)-3-Fluoro-9-((1S,2R)-2-fluoro-1-hydroxy-7-((trifluoromethyl)sulfonyl)-2,3-dihydro-1H-inden-4-yl)-6,7,8,9-tetrahydro-5H-benzo[7]cycloalkene-1-carbonitrile 10
  • Step 1 ((7-bromo-2-fluoro-4-((trifluoromethyl)sulfonyl)-1H-inden-3-yl)oxy)(tert-butyl)dimethylsilane 11a
  • reaction solution was quenched with ice water (15 mL), extracted with dichloromethane (20 mL x 2), the organic phases were combined, washed with saturated brine (15 mL), dried over anhydrous sodium sulfate, and concentrated to obtain a crude product.
  • Step 4 4-(1,3-difluoro-6,7-dihydro-5H-benzo[7]cycloalken-9-yl)-2,2-difluoro-7-((trifluoromethyl)sulfonyl)-2,3-dihydro-1H-inden-1-ol 11d
  • Step 5 (S)-4-((R)-2,4-difluoro-6,7,8,9-tetrahydro-5H-benzo[7]cycloalken-5-yl)-2,2-difluoro-7-(trifluoromethanesulfonyl)-2,3-dihydro-1H-inden-1-ol 11
  • Step 4 8-(7-chloro-2-fluoro-1-oxo-2,3-dihydro-1H-inden-4-yl)-3-fluoro-5,6-dihydronaphthalene-1-carbonitrile 12e
  • the reaction solution was cooled to room temperature, and ethyl acetate (10 mL x 2) was added for extraction.
  • the organic phases were combined, washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and concentrated.
  • Step 5 8-(7-(dimethylphosphoryl)-1-oxo-2,3-dihydro-1H-inden-4-yl)-3-fluoro-5,6-dihydronaphthalene-1-carbonitrile 12f
  • the reaction solution was cooled to room temperature, quenched with water (10 mL), extracted with ethyl acetate (10 mL x 2), and the organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and concentrated.
  • the crude product was purified by Prep-TLC to obtain the title compound 12f (71 mg, yield 13.86%) as a green oil.
  • Step 6 8-(7-(dimethylphosphoryl)-2-fluoro-1-oxo-2,3-dihydro-1H-inden-4-yl)-3-fluoro-5,6-dihydronaphthalene-1-carbonitrile 12g
  • Step 7 8-[(1S,2R)-7-(dimethylphosphoryl)-2-fluoro-1-hydroxy-2,3-dihydro-1H-inden-4-yl]-3-fluoro-5,6-dihydronaphthalene-1-carbonitrile 12h
  • Step 8 (R)-8-((1S,2R)-7-(dimethylphosphoryl)-2-fluoro-1-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-fluoro-5,6,7,8-tetrahydronaphthalene-1-carbonitrile 12
  • Step 5 9-[(1S)-7-chloro-2,2-difluoro-1-(methoxymethoxy)-2,3-dihydro-1H-inden-4-yl]-1,3-difluoro-6,7-dihydro-5H-benzo[7]cycloolefin 13e
  • Step 6 5-[(3S)-7-(1,3-difluoro-6,7-dihydro-5H-benzo[7]cycloalken-9-yl)-2,2-difluoro-3-(methoxymethoxy)-2,3-dihydro-1H-inden-4-yl]-1-methyl-1H-pyrazole 13f
  • the reaction of the raw material was completed by TLC monitoring.
  • the reaction solution was cooled to room temperature, extracted with ethyl acetate (50 mL), washed with saturated brine (50 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated.
  • Step 7 (1S)-4-(1,3-difluoro-6,7-dihydro-5H-benzo[7]cycloalkene-9-yl)-2,2-difluoro-7-(1-methyl-1H-pyrazol-5-yl)-2,3-dihydro-1H-inden-1-ol 13g
  • Step 8 (1S)-4-(2,4-difluoro-6,7,8,9-tetrahydro-5H-benzo[7]cycloalken-5-yl)-2,2-difluoro-7-(1-methyl-1H-pyrazole-5-yl) 2,3-dihydro-1H-inden-1-ol 13
  • Test Example 1 Activity detection of compounds inhibiting the binding of HIF-2 ⁇ and HIF-1 ⁇
  • PT-2977 was used as a positive control in this experiment.
  • the compounds of the present invention have excellent HIF-2 ⁇ inhibitory activity.
  • 786-O cells in logarithmic phase growth were inoculated into 96-well plates at a cell concentration of 4000 cells per ml of culture medium, 180 ⁇ L per well, and the 96-well plates were placed in an incubator at 37°C and 5% CO 2 overnight.
  • PT-2977 was used as a positive control in this experiment.
  • the cells used in this experiment were 786O-HRE-Luciferase stable transfection cell lines (sequence 9*HRE-Luci).
  • the experiment was conducted when the 786O-HRE-Luci stable transfection cell lines were in the logarithmic growth phase and cultured in a culture medium (RPMI1640MEDIUM, purchased from GIBCO). When the cell confluence reached 80-90%, the culture medium was discarded, PBS was was washed three times, trypsin (purchased from BI) was added to digest the cells, and the cells were washed with serum-containing culture medium to terminate cell digestion. After the cells were collected, they were centrifuged and washed once with PBS to remove the phenol red in the culture medium. The cells were resuspended to an appropriate concentration to detect the cell density and viability, and the cell viability was ensured to be above 95% before the next experiment.
  • the cells were seeded into 384-well plates, 3000 cells/well, 30 ⁇ L of culture medium, and the compounds were added to make the final concentrations 10000, 3333, 1111, 370, 123, 41.1, 13.7, 4.6, 1.5, and 0.5 nM, respectively.
  • the cells were placed at 37°C and 5% CO 2 and incubated for 72 h.
  • ONE-Glo TM Luciferase Assay System purchased from Promega was added to a 384-well plate at 30 ⁇ L/well, and the luminescence value was detected by an ELISA instrument.
  • the inhibition rate (%) was calculated based on the RLU (Record Luminesence) signal value of each well, and then the IC 50 of the corresponding compound was calculated by fitting using Graphpad 9.0.
  • PT-2977 was used as a positive control in this experiment.
  • the compound of the present invention has advantages over existing positive compounds in terms of solubility, in vivo clearance rate and bioavailability.
  • the present invention illustrates the inhibitory activity of the present invention through the above examples, thereby proving its therapeutic use in the treatment or alleviation of diseases related to overexpression.
  • the compound of the present invention has excellent solubility in water and indicates metabolic stability in vivo, and has very broad industrial application prospects.
  • the present invention is not limited to the above embodiments, which does not mean that the present invention must rely on the above embodiments to be implemented. Those skilled in the art should understand that any improvement of the present invention, equivalent replacement of various raw materials of the product of the present invention, addition of auxiliary components, selection of specific methods, etc., all fall within the protection scope and disclosure scope of the present invention.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Communicable Diseases (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne un composé de formule (I) ou un sel pharmaceutiquement acceptable, un ester, un isomère optique, un tautomère, un stéréoisomère, un polymorphe, un solvate, un N-oxyde, un composé marqué par un isotope, un métabolite, un chélate, un complexe, un composé d'inclusion ou un promédicament de celui-ci, une composition pharmaceutique le comprenant, et son utilisation en tant qu'inhibiteur du facteur 2α induit par l'hypoxie (HIF-2α), et son utilisation dans la préparation de médicaments pour le traitement de maladies associées à HIF-2α .
PCT/CN2023/121015 2022-09-27 2023-09-25 Dérivé de benzo[7]annulène, composition pharmaceutique le comprenant, et utilisations médicales associées WO2024067463A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202211184177.2 2022-09-27
CN202211184177 2022-09-27

Publications (1)

Publication Number Publication Date
WO2024067463A1 true WO2024067463A1 (fr) 2024-04-04

Family

ID=90395158

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2023/121015 WO2024067463A1 (fr) 2022-09-27 2023-09-25 Dérivé de benzo[7]annulène, composition pharmaceutique le comprenant, et utilisations médicales associées

Country Status (2)

Country Link
CN (1) CN117776987A (fr)
WO (1) WO2024067463A1 (fr)

Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0200455A2 (fr) * 1985-04-22 1986-11-05 Novo Nordisk A/S 2,3,4,5-tetrahydro-1H-3-benzazépines substituées en position 5
WO1996010012A1 (fr) * 1994-09-29 1996-04-04 The Du Pont Merck Pharmaceutical Company Nouveaux inhibiteurs de la prostaglandine-synthase
WO1999067244A1 (fr) * 1998-06-20 1999-12-29 Bayer Aktiengesellschaft Imidazotriazinones a substitution 7-alkyle et cycloalkyle
WO2006044753A2 (fr) * 2004-10-19 2006-04-27 Smithkline Beecham Corporation Composes chimiques
CN1922147A (zh) * 2004-03-12 2007-02-28 阿纳里特康股份有限公司 作为类胰岛素生长因子第1类受体抑制剂的新颖杂环化合物
CN101437814A (zh) * 2006-05-31 2009-05-20 弗·哈夫曼-拉罗切有限公司 作为单胺再摄取抑制剂的苯并氮杂衍生物
WO2010012812A1 (fr) * 2008-07-31 2010-02-04 Westfälische Wilhelms Universität Münster Benzazépines et benzazocines en tant que ligands de récepteurs sigma
JP2011111419A (ja) * 2009-11-27 2011-06-09 Otsuka Pharmaceut Co Ltd 医薬
US20160272572A1 (en) * 2015-02-16 2016-09-22 Purdue Research Foundation Adenylyl cyclase inhibitors for neuropathic and inflammatory pain
US20180140569A1 (en) * 2015-04-17 2018-05-24 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
US20180162807A1 (en) * 2015-03-11 2018-06-14 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
WO2019089412A1 (fr) * 2017-11-01 2019-05-09 Merck Sharp & Dohme Corp. Nouveaux composés de tétrahydroquinoline substitués utilisés en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido)
WO2021093724A1 (fr) * 2019-11-15 2021-05-20 武汉光谷亚太医药研究院有限公司 Nouveau composé dérivé de 2,3-hydrindène, procédé de préparation et application
CN113226310A (zh) * 2019-01-08 2021-08-06 杏林制药株式会社 15-pgdh抑制剂
US20210317079A1 (en) * 2020-03-19 2021-10-14 Arcus Biosciences, Inc. Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0200455A2 (fr) * 1985-04-22 1986-11-05 Novo Nordisk A/S 2,3,4,5-tetrahydro-1H-3-benzazépines substituées en position 5
WO1996010012A1 (fr) * 1994-09-29 1996-04-04 The Du Pont Merck Pharmaceutical Company Nouveaux inhibiteurs de la prostaglandine-synthase
WO1999067244A1 (fr) * 1998-06-20 1999-12-29 Bayer Aktiengesellschaft Imidazotriazinones a substitution 7-alkyle et cycloalkyle
CN1922147A (zh) * 2004-03-12 2007-02-28 阿纳里特康股份有限公司 作为类胰岛素生长因子第1类受体抑制剂的新颖杂环化合物
WO2006044753A2 (fr) * 2004-10-19 2006-04-27 Smithkline Beecham Corporation Composes chimiques
CN101437814A (zh) * 2006-05-31 2009-05-20 弗·哈夫曼-拉罗切有限公司 作为单胺再摄取抑制剂的苯并氮杂衍生物
WO2010012812A1 (fr) * 2008-07-31 2010-02-04 Westfälische Wilhelms Universität Münster Benzazépines et benzazocines en tant que ligands de récepteurs sigma
JP2011111419A (ja) * 2009-11-27 2011-06-09 Otsuka Pharmaceut Co Ltd 医薬
US20160272572A1 (en) * 2015-02-16 2016-09-22 Purdue Research Foundation Adenylyl cyclase inhibitors for neuropathic and inflammatory pain
US20180162807A1 (en) * 2015-03-11 2018-06-14 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
US20180140569A1 (en) * 2015-04-17 2018-05-24 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
WO2019089412A1 (fr) * 2017-11-01 2019-05-09 Merck Sharp & Dohme Corp. Nouveaux composés de tétrahydroquinoline substitués utilisés en tant qu'inhibiteurs de l'indoléamine 2,3-dioxygénase (ido)
CN113226310A (zh) * 2019-01-08 2021-08-06 杏林制药株式会社 15-pgdh抑制剂
WO2021093724A1 (fr) * 2019-11-15 2021-05-20 武汉光谷亚太医药研究院有限公司 Nouveau composé dérivé de 2,3-hydrindène, procédé de préparation et application
US20210317079A1 (en) * 2020-03-19 2021-10-14 Arcus Biosciences, Inc. Tetralin and tetrahydroquinoline compounds as inhibitors of hif-2alpha

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DÓRA SZALÓKI VARGÁNÉ: "[1,5]-Hydride Shift-Cyclization versus C(sp2)-H Functionalization in the Knoevenagel-Cyclization Domino Reactions of 1,4- and 1,5-Benzoxazepines", MOLECULES, MDPI AG, CH, vol. 25, no. 6, 11 March 2020 (2020-03-11), CH , pages 1265, XP093152128, ISSN: 1420-3049, DOI: 10.3390/molecules25061265 *
LI, JIANQING ET AL.: "Enantioselective Synthesis of BMS-911278: a Triple Reuptake Inhibitor", TETRAHEDRON ASYMMETRY, vol. 28, no. 1, 28 December 2016 (2016-12-28), XP029877870, ISSN: 0957-4166, DOI: 10.1016/j.tetasy.2016.12.003 *

Also Published As

Publication number Publication date
CN117776987A (zh) 2024-03-29

Similar Documents

Publication Publication Date Title
CN106103416B (zh) 作为trpm8拮抗剂的氮杂螺衍生物
WO2020177653A1 (fr) Dérivé de pyrazine et son application dans l'inhibition de shp2
TWI617546B (zh) 咪唑啉類衍生物、其製備方法及其在醫藥上的應用
CN108430998A (zh) 氮杂双环衍生物及其制备方法和用途
TWI654172B (zh) 環烷基甲酸類衍生物、其製備方法及其在醫藥上的應用
TW201718561A (zh) 苯並呋喃類衍生物、其製備方法及其在醫藥上的應用
TWI732810B (zh) 苯并哌啶類衍生物、其製備方法及其在醫藥上的應用
WO2016169421A1 (fr) Dérivé imidazo isoindole, méthode de préparation correspondante et utilisation médicale correspondante
TW202128668A (zh) 并環類衍生物、其製備方法及其在醫藥上的應用
WO2023088441A1 (fr) Inhibiteur de kif18a
WO2020182018A1 (fr) Composé hétérocyclique azoté, son procédé de préparation et son utilisation
WO2019158051A1 (fr) Composé spiro utilisé en tant qu'inhibiteur de l'indoléamine-2,3-dioxygénase
CN109071548A (zh) 可用于治疗尤其是癌症的吡咯并咪唑衍生物或其类似物
WO2021208918A1 (fr) Composés tricycliques servant d'inhibiteurs d'egfr
WO2019179515A1 (fr) Inhibiteur de récepteur, composition pharmaceutique le comprenant et son utilisation
WO2023011513A1 (fr) Inhibiteur de shp2, composition pharmaceutique le comprenant et son application
KR20230027161A (ko) 비시클릭 화합물 및 이의 응용
WO2022166860A1 (fr) Inhibiteur de pim kinase
CN113574058A (zh) 吲哚类大环衍生物、其制备方法及其在医药上的应用
CN110198941B (zh) 吡咯并吡啶类n-氧化衍生物及其制备方法和应用
WO2023274396A1 (fr) Composé de benzazépine hétérocyclique et son utilisation en médecine
WO2024067463A1 (fr) Dérivé de benzo[7]annulène, composition pharmaceutique le comprenant, et utilisations médicales associées
WO2021227904A1 (fr) Dérivé amide polycyclique servant d'inhibiteur de cdk9, son procédé de préparation et son utilisation
WO2020048380A1 (fr) Dérivé de 1,7-naphtyridine, son procédé de préparation et d'utilisation
WO2024061366A1 (fr) Composé à petites molécules ayant une structure aryle phosphorylé et son utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23870694

Country of ref document: EP

Kind code of ref document: A1